On July 2, Gilead Sciences rose 3.06% in regular trading, trading at $129.86/share, with turnover of $76.69 million.

The move follows the FDA's approval of Trodelvy for first-line treatment of adults with advanced triple-negative breast cancer. The approval allows Trodelvy to be used as a standalone treatment for patients not candidates for PD-1 inhibitor-based therapy, or in combination with Merck's Keytruda for patients whose tumors express PD-L1. The National Comprehensive Cancer Network simultaneously updated its guidelines to recommend Trodelvy, with or without Keytruda, as a category 1 preferred first-line treatment option for metastatic triple-negative breast cancer regardless of PD-L1 status.

This approval marks a significant commercial expansion for Trodelvy, elevating it from later-line to first-line core therapy. The milestone follows the European Commission's marketing authorization granted on June 23 for the same indication. Combined with the company's HIV combination therapy receiving FDA priority review and recent acquisitions of Arcellx and Tubulis, Gilead's oncology and antiviral dual-pipeline growth thesis continues to strengthen.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)